UNSPSC 51413904: Dramedilol

This classification denotes a vasodilating agent with the molecular formula C20H29N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8PW276HX8U, chemically known as acetone (- )-(6(3-((3,4-dimethoxyphenethyl)amino)-2-hydroxypropoxy)-3-pyridazinyl)hydrazone. but generally known as dramedilol, which bears US NIH Compound Identifier 208896. European Medicines Agency schedules Dramedilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06396MIG.

UNSPSC 51413904 Dramedilol is a Commodity code that encompasses emergency and critical-care medications supplied to state and local health systems, fire rescue services, and pharmacy benefit programs. State and local governments procure these medications primarily through fire departments, emergency medical services, health and human services agencies, and cooperative purchasing alliances that serve multi-state hospital networks and government employee health plans. The work involves supplying pharmaceutical products with strict quality controls, including cGMP certification, FDA compliance, expiration-date management, Safety Data Sheets documentation per OSHA standards, and often direct relationships with authorized wholesalers or direct-to-manufacturer arrangements that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with epinephrine, labetalol, adenosine, and diltiazem, with responses due April 8, 2026 and an estimated contract value of $40,000; the solicitation carried a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted an RFI in April 2026 to assess vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's interest in bypassing traditional PBM and GPO distribution channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with responses due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with contract terms beginning July 1, 2026 and performance penalties of $200 to $1,500 per violation for compliance failures.